AxioMed Taps Chairman With Ortho, Entrepreneurial Experience
This article was originally published in The Gray Sheet
Executive Summary
New AxioMed Chairman Robert Compton's strong orthopedic industry background should aid the Freedom artificial lumbar disc developer as it moves toward a commercialization strategy
You may also be interested in...
Financings In Brief
Xtent: Menlo Park, Calif.-based firm will use proceeds of $25 mil. financing led by Morgenthaler Ventures to finish development and launch its Custom Nx coronary stent - which elutes Biosensors' Biolimus A9 drug - in the European market by Q4 2006 (1"The Gray Sheet" May 31, 2004, p. 17). Xtent will commence enrollment of a 100-person clinical trial this summer to support a CE mark. The DES system is meant to treat long, diffuse lesions and multiple lesions more rapidly and accurately than currently available devices by using a delivery system that deploys a divisible stent to different parts of the vessel, thereby minimizing catheter exchange, Xtent explains. Following EU marketing, the 48-person company will begin a 1,500-subject pivotal trial to support U.S. approval, expected in 2008. President & CEO Greg Casciaro joined Xtent last September. He previously served as CEO of Healos bone graft substitute manufacturer Orquest, which J&J/DePuy acquired in 2003 (2"The Gray Sheet" Feb. 3, 2003, In Brief)...
Financings In Brief
Xtent: Menlo Park, Calif.-based firm will use proceeds of $25 mil. financing led by Morgenthaler Ventures to finish development and launch its Custom Nx coronary stent - which elutes Biosensors' Biolimus A9 drug - in the European market by Q4 2006 (1"The Gray Sheet" May 31, 2004, p. 17). Xtent will commence enrollment of a 100-person clinical trial this summer to support a CE mark. The DES system is meant to treat long, diffuse lesions and multiple lesions more rapidly and accurately than currently available devices by using a delivery system that deploys a divisible stent to different parts of the vessel, thereby minimizing catheter exchange, Xtent explains. Following EU marketing, the 48-person company will begin a 1,500-subject pivotal trial to support U.S. approval, expected in 2008. President & CEO Greg Casciaro joined Xtent last September. He previously served as CEO of Healos bone graft substitute manufacturer Orquest, which J&J/DePuy acquired in 2003 (2"The Gray Sheet" Feb. 3, 2003, In Brief)...
LDR Spine Joins Ranks Of Firms Pursuing Second Generation Artificial Disc
LDR Spine will look to partner with or be acquired by a larger orthopedic company upon approval of its second-generation Mobidisc artificial disc